AI drug discovery platforms bring machine learning, generative models and predictive analytics into the core of target identification, virtual screening, lead design and early ADMET assessment. By 2026 this category—exemplified by providers such as Chai Discovery (generative chemistry and lead optimization), Atomwise (deep‑learning–driven structure/ligand scoring and virtual screening) and Insilico (end‑to‑end generative biology and target‑to‑lead pipelines)—is becoming a standard complement to experimental workflows rather than an experimental novelty. Relevance and timing: rising R&D costs, shorter product cycles, advances in large models and graph/neural representations of molecules, and demand for faster, more reproducible preclinical hypotheses have pushed pharmaceutical teams to adopt AI platforms. At the same time, regulatory expectations and the need for explainability, robust validation and data governance mean platforms must integrate with enterprise data stacks and research workflows. Ecosystem and tool roles: AI Tool Marketplaces and Data Platforms provide curated models and interoperable datasets; AI Research Tools and Data Analytics Tools enable hypothesis generation, batch screening, and retrospective validation. Complementary infrastructure includes research search engines (Researchspace) for literature and provenance, enterprise assistants (IBM watsonx Assistant, Claude family, Microsoft 365 Copilot) to operationalize workflows and reporting, knowledge bases (Notion) to capture protocols and decisions, and document automation/indexing tools (AIindexer, PDF-app.net) to process literature and regulatory submissions. Practical focus for teams: evaluate model types (generative vs physics‑augmented), data lineage, integration with lab informatics, validation pathways, and vendor support for reproducibility and regulatory traceability. These criteria determine where AI platforms add actionable value in the drug discovery pipeline.